AIHealthcare

Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company that uses an AI-native, end-to-end platform—Recursion OS—to decode biology and industrialize drug discovery and development across oncology, rare disease, neuroscience, immunology, and other areas of unmet medical need. The company combines high-throughput automated biology and chemistry with large-scale proprietary multimodal datasets and advanced machine learning (including its LLM-based platform Lowe) to discover and optimize novel medicines more quickly and at greater scale, positioning itself as a frontrunner in AI-driven drug development.